316 results on '"Wagle, N."'
Search Results
2. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
3. Prevalence and mutational determinants of high tumor mutation burden in breast cancer
4. 137P First-in-human results from a phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
5. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.
6. A Genomic Score to Predict Local Control among Patients with Brain Metastases Managed with Radiation
7. Genomic Predictors of Leptomeningeal Disease Development among Patients with Brain Metastases
8. 1026P Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors
9. Govindrav Babaji Joshi Goes to Madras: A ‘Diary’ of the Third Indian National Congress
10. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia
11. Social Groups and Ranking: An Aspect of Ancient Indian Social Life Derived from the Pali Canonical Texts
12. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
13. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
14. ESTIMATING AND MAPPING CHLOROPHYLL-A CONCENTRATION OF PHEWA LAKE OF KASKI DISTRICT USING LANDSAT IMAGERY
15. EFFECT OF POST-SHOOTING BUNCH SPRAY OF GROWTH HORMONE AND FERTILIZER ON YIELD ATTRIBUTING CHARACTERS OF BANANA.
16. B-Lymphocyte Signaling Receptors and the Control of Class-II Antigen Processing
17. Prevalence and mutational determinants of high tumor mutation burden in breast cancer
18. Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole exome sequencing (WES)
19. Abstract P4-04-02: Identifying ERBB-2 activating mutations (mts) in HER2 negative tumors for clinical trials – Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practice
20. Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancer
21. Abstract P5-12-02: PTEN alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)
22. Abstract P5-17-01: Patient-derived organoid models of inflammatory breast cancer
23. Abstract PD9-03: The genomic landscape of de novo metastatic breast cancer (MBC)
24. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
25. Abstract GS3-07: Genome-wide copy number analysis of chemotherapy-resistant metastatic triple-negative breast cancer from cell-free DNA
26. Abstract PD4-01: The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER+ breast cancer
27. Abstract P2-01-04: The whole transcriptional landscape of circulating tumor cells compared to metastases in stage IV breast cancer
28. Cobalt as a model for zinc in biological systems
29. Journal of the Society for Arts, Vol. 50, no. 2574
30. Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer
31. Abstract P3-03-08: A large-scale functional screen to identify resistance mechanisms to selective estrogen receptor degraders fulvestrant and GDC-810 in ER+ breast cancer
32. Abstract CS1-1: The genomics of metastatic breast cancer: What are we learning?
33. Abstract P3-04-08: The role of HER2 mutations in resistance to endocrine therapy in ER+ breast cancer
34. Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC)
35. Abstract OT2-05-03: The metastatic breast cancer project: A national direct-to-patient research initiative to accelerate genomics research
36. Abstract S3-03: Nuclear FGFR1 interaction with estrogen receptor (ER) α is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer
37. Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
38. Carbonic anhydrase as a model for matrix metalloproteinase inhibition
39. "Reinterpreting Indian History"
40. Jains in the World: Religious Values and Ideology in India . By John E. Cort . New York: Oxford University Press, 2001. Pp. xii+267. $50.00.
41. A Study of Kinship Groups in the Rāmāṇaya of Vālmīki
42. 428 Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations
43. Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer
44. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy
45. 785P - Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC)
46. Abstract P5-18-03: Clinicopathological features among patients with HER2-positive breast cancer with prolonged response to trastuzumab based therapy
47. Transfer learning for dynamic RF environments
48. Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma
49. S3-4: ER Downregulation with Fulvestrant in Combination with pan-PI3K Inhibitor BKM120 Synergizes Against ER+/PI3K-Mutant Breast Cancer Xenografts In Vivo.
50. Tumor genomic profiling of FFPE samples by massively parallel sequencing.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.